KoBioLabs, Inc (KOSDAQ:348150)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,710.00
+45.00 (0.96%)
At close: May 14, 2026
Market Cap89.62B -17.9%
Revenue (ttm)69.29B +1.4%
Net Income-6.33B
EPS-326.00
Shares Out19.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume58,866
Average Volume104,463
Open4,665.00
Previous Close4,665.00
Day's Range4,590.00 - 4,785.00
52-Week Range4,180.00 - 8,730.00
Beta0.23
RSI33.63
Earnings Daten/a

About KoBioLabs

KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 348150
Full Company Profile

Financial Performance

In 2025, KoBioLabs's revenue was 69.29 billion, an increase of 1.36% compared to the previous year's 68.36 billion. Losses were -6.33 billion, 19.5% more than in 2024.

Financial Statements